Q3 2018 RESULTS

NET REVENUE $3.9 BILLION

PERFORMANCE NET INCOME PER SHARE* $4.25

*GAAP Loss Per Share $0.11

ALLERGAN RAISED FULL-YEAR 2018 GUIDANCE FOR NET REVENUE AND NON-GAAP PERFORMANCE NET INCOME PER SHARE

R&D PIPELINE ADVANCEMENTS INCLUDE CARIPRAZINE AND UBROGEPANT

PRO-FORMA DEBT REDUCTION OF $750 MILLION**

REVENUE DRIVEN BY GROWTH IN TOP PROMOTED PRODUCTS:

*Botox*, *Vraylar*, *Juvederm*, *Lo Loestrin Fe*, *AlloDerm*

**$750M represents the portion of the $1.76B debt repurchase in Q3 2018 that is not expected to be refinanced**

*Performance net income per share refers to non-GAAP metrics. Please refer to the GAAP to non-GAAP tables in October 30, 2018 Press Release on Allergan.com for a reconciliation of our non-GAAP results***